Geriatric Problem	% present
Lack of Social Support	10
Incomplete Vaccinations	53
Problems with Cognition	31
Problems with Chronic Pain	90
Problems with Dizziness	44
Problems with Mobility	41
Problems with Unintentional Weight Loss	30
Inappropriate Medications present	17
Polypharmacy present	81
Frailty present	46
Short Physical Performance Battery low	57

Acknowledgments: None

Disclosure of Interests: Anna Berrisch: None declared, Ioana Andreica: None declared, Styliani Tsiemi: None declared, David Kiefer Grant/research support from: Novartis, Uta Kiltz Grant/research support from: AbbVie, Amgen, Biogen, Novartis, Pfizer, Consultant of: AbbVie, Biocad, Eli Lilly and Company, Grünenthal, Janssen, Novartis, Pfizer, UCB, Speakers bureau: AbbVie, MSD, Novartis, Pfizer, Roche, UCB, Xenofon Baraliakos Grant/research support from: Grant/research support from: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB and Werfen, Consultant of: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB and Werfen, Speakers bureau: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB and Werfen, Juergen Braun Grant/research support from: AbbVie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, Eli Lilly and Company, Medac, MSD (Schering Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis, and UCB Pharma, Consultant of: AbbVie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Eli Lilly and Company, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis, and UCB Pharma, Speakers bureau: AbbVie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Eli Lilly and Company, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis, and UCB Pharma, Bjoern Buehring Grant/research support from: GE/Lunar, Kinemed, Consultant of: Gilead, AbbVie, Lilly, GE/Lunar, Janssen, Amgen, Speakers bureau: UCB

DOI: 10.1136/annrheumdis-2020-eular.2815

SAT0580

ANALYSIS OF ANAS/DFS70 PATTERN IN A LARGE COHORT OF AUTOIMMUNE/AUTOINFLAMMATORY DISEASES COMPARED WITH FIRST DEGREE RELATIVES AND HEALTHY CONTROLS EVALUATED IN A SINGLE HOSPITAL FROM COLOMBIA.

C. Romero-Sánchez^{1,2,3}, O. J. Calixto⁴, V. Romero-A^{1,2}, A. Vargas⁵, L. Castro⁶, J. Amador⁶, P. Lopez-Mojica⁶, D. Marin⁶, D. Acero-M^{2,7}, M. Acevedo^{2,7}, D. Rincón-Riaño¹, J. M. Bello-Gualtero^{1,2}. ¹Rheumatology and Immunology Department Hospital Militar Central, Bogota, Colombia; ²Clinical Immunology Group- Hospital Militar, School of Medicine, Universidad Militar Nueva Granada, Bogota, Colombia; ³Universidad El Bosque, Cellular and Immunology Group /InmuBo, Bogota, Colombia; ⁴Internal Medicine Department Hospital Militar Central, Universidad Militar Nueva Granada, Bogota, Colombia; ⁵Bacteriology degree, Faculty of Basic Sciences, Universidad Colegio Mayor de Cundinamarca, Bogota, Colombia; ⁶Dermatology Department Hospital

Militar Central, Universidad Militar Nueva Granada, Bogota, Colombia;

⁷Immunology Laboratory, Hospital Militar Central, Bogota, Colombia

Background: Autoimmune diseases have a broad phenotypic spectrum, with great variability in clinical manifestations. Anti-DFS70/LEDGFp75 (ANAS/DFS70) antibodies have attracted interest as a positive result in patients without clinical evidence of autoimmune systemic rheumatic disease (SARD). It has been proven in non-rheumatic inflammatory diseases and in "apparently healthy" individuals.

Objectives: To assess ANAS/DFS70 performance in a large population with autoimmune/autoinflammatory diseases compared with first degree relatives and healthy controls.

Methods: A cross-sectional study was conducted. We analysed 531 individuals between 18-65 years old, 101 rheumatoid arthritis (RA) patients (ACR/EULAR 2010 classification criteria), 137 relatives from RA, 60 psoriasis (Ps) patients (Colombian classification consensus), 47 Undifferentiated connective tissue diseases (UCTD) patients and 186 healthy controls matched by age and sex. The healthy control group were individuals who lived and work similarly like those patients those criteria of exclusion criteria were to present autoimmune or auto-inflammatory disease, infectious, neoplasms, diabetes, antibiotic treatment, pregnancy or lactation, consanguinity with autoimmune entities. Ethical Committee approved.

The determination of ANAS-HEp2 antibodies (ANA-Hep-2 AESKU.Dignostic®, Autoantibody test SYSTEM IMCO DIAGNOSTICS REF 1103® and ANA-Hep-2 AESKU.Dignostic®) was carried out. The positive results (standard AC-2) are used as a confirmatory test the determination of ANAS / DFS70: AUTOANTIBODY TEST SYSTEM IMCO DIAGNOSTICS (Knocked out, for the psip gene) REF 1108® and CytoBead ANA Generic Assays ref 8065 ® by indirect immunofluorescence-IFI technique. In addition, serum levels of C-reactive protein (PCR), erythrocyte sedimentation rate (ESR), IgG/IgA antibodies against citrullinated peptide (ACPA), and rheumatoid factor (RF). Absolute and relative frequencies were established.

Results: 531 participants were included: RA 19%, 25.8% RA relatives, Ps 11.3%, UCTD 8.9%, and 35% healthy controls. RA mean age was 41.8±12.2 years, female 82.2%, with ANA test(+) result 42%. In Ps mean age 49.1±15.7 years, female 53.3%, ANA test(+) 41.7%. UCTD mean age 41.3±15.2 years, female 85.1%, and ANA test(+) 78.7%. Relatives of RA mean age 38.7±12.2 years, female 73%, ANA test(+) 26.3%. And healthy controls mean age 41.3±12.2 years, female 74.7%, and ANA test(+) 26.9%.

ANA/DFS70 was positive in a 6.4% in UCTD, 3.2% in healthy controls, 1.7% in Ps, 1.5% in Relatives of RA, no RA had positive results. These 12 participants were negative for acute phase reactants (ESR[-] 83.3% and CRP[-] 66.6%), as well as they were all negative for RF and two were positive for APCA from UCTD.

Conclusion: ANAS/DFS70 autoantibodies were present in very low frequency in patients with SARD. Thus, patients with a positive result tend to have a mild or non-progressing phenotype of autoimmune/inflammatory diseases, as UCTD. This is the first time ANA/DFS70 are tested in a large population cohort in Latin American countries which coincide with previous results in RA and RA relatives.

Acknowledgments: Hospital Militar Central-Universidad El Bosque-Immco diagnosis-Dizar Ltda and Generic Assay-Medipan.

Disclosure of Interests: Consuelo Romero-Sánchez: None declared, Omar-Javier Calixto Employee of: Worked in Janssen Cilag as medical manager from 2016 to 2018, V Romero-A: None declared, A Vargas: None declared, Luis Castro: None declared, Julio Amador: None declared, Pedro Lopez-Mojica: None declared, Daniela Marin: None declared, Diana Acero-M: None declared, M Acevedo: None declared, Diana Rincón-Riaño: None declared, Juan Manuel Bello-Gualtero: None declared

DOI: 10.1136/annrheumdis-2020-eular.5082

SAT0581

SERIOUS INFECTION RATES WITH BIOLOGICAL DISEASE MODIFYING ANTI-RHEUMATIC AGENTS (bDMARDS) AND PREDISPOSING FACTORS: A 5-YEAR RETROSPECTIVE REVIEW

K. Celkys¹, J. Ly¹, M. Soden¹. ¹Townsville Hospital and Health Service, Townsville, Australia

Background: Biological and targeted synthetic disease modifying anti-rheumatic agents (bDMARDS) increase the risk of serious infections (SIs), however there is limited 'real-world' evidence comparing the relative risk of SI for individual bDMARDS. (1,2)

Objectives: This study examines the rates of SIs in a non-select Australian Northern Queensland (NQ) cohort of patients with various rheumatic diseases receiving treatment with a bDMARD, to define predisposing factors and directly compare the bDMARDS.

Methods: A retrospective review was performed for all patients who received a bDMARD through the Townsville Hospital Rheumatology Department over the

5-year period between June 2013 and May 2018. Episodes of a SI were defined as infection requiring admission or use of intravenous antibiotics. For each bDMARD the rate of SI per 100 patient years (PYs) was calculated and patient demographics and comorbidities were analysed. Between group differences were assessed using independent samples t-tests or ANOVA. Where assumptions were violated, Mann-Whitney U tests or Kruskal-Wallis tests were used. For categorical variables, chi-square tests were used, except when assumptions were violated when Fisher's Exact tests were used.

Results: 296 patients received bDMARDs with an overall SI rate of 11.7/100PYs. There was no significant difference in presence of SI by disease type with 24% of patients with rheumatoid arthritis versus 19% with psoriatic arthritis, 14% with ankylosing spondylitis and 29% with "other" ($X^2=3.11$; $df=3$; $p=0.37$). Respiratory tract infections were the most common infection (46%) followed by skin and soft tissue infections (23%). The highest incidence rate of SI occurred with rituximab (29.72 SI/100PYs) followed by certolizumab (22.50 SI/100PYs) and tocilizumab (15.00 SI/100PYs). Duration of time on a bDMARD, disease duration and use of methotrexate or leflunomide were not shown to significantly increase the risk of SI for the entire cohort. The characteristics which were shown to significantly increase SI rates were; prednisone use, increasing age, chronic pulmonary comorbidity and specifically in those with rheumatoid arthritis male gender and total duration of bDMARD use.

Conclusion: In this real-world NQ cohort of patients treated with a bDMARD for a rheumatic disease, we have identified a number of factors potentially contributing to the risk of the development of SIs. This study provides valuable data on SI rates in an Australian 'real-world' cohort that may assist clinicians' choice of bDMARD in patients with a high baseline risk of infection and highlights the importance of minimising prednisone use in patients on bDMARDs.

References:

- [1] Ramiro S, Sepriano A, Chatzidionysiou K, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. *Ann Rheum Dis*. 2017;76:1093–1101.
- [2] Singh J, Wells G, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. *Cochrane Database Syst Rev*. 2011;16:CD008794.

Disclosure of Interests: Kate Celkys: None declared, Jason Ly: None declared, Muriel Soden Speakers bureau: Speaker Fees from Pfizer in 2016

DOI: 10.1136/annrheumdis-2020-eular.1137

SAT0582 RISK OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES: A NATIONWIDE, POPULATION-BASED COHORT STUDY

H. H. Chen^{1,2}, K. H. Ng², W. C. Chao³, C. H. Lin¹. ¹Taichung Veterans General Hospital, Department of Medical Research, Taichung, Taiwan, Republic of China; ²Taichung Veterans General Hospital, Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung, Taiwan, Republic of China; ³Taichung Veterans General Hospital, Department of Critical Care Medicine, Taichung, Taiwan, Republic of China

Background: To date, very few studies had investigated the epidemiology of interstitial lung disease (ILD) among patients with systemic autoimmune rheumatic disease (SARD).

Objectives: To study the risk of interstitial lung disease (ILD) among patients with various systemic autoimmune rheumatic diseases (SARDs) including rheumatoid arthritis (RA), dermatomyositis (DMtis), polymyositis (PM), systemic sclerosis (SSc), systemic lupus erythematosus (SLE), and primary Sjögren's syndrome (pSS).

Methods: Using 1997–2013 claims data from the Taiwanese National Health Insurance Research Database, we identified 63,277 newly diagnosed patients with various SARDs after excluding those with overlapping SARD diagnoses from 2001–2013 and randomly selected 253,108 non-SARD subjects matching (1:4) SARD patients for SARD diagnosis, age, sex and the year of the index date. We calculated the incidence rates (IRs) of ILD (ICD-9 code 515) in various SARD groups and the corresponding non-SARD comparison groups and estimated the IR ratios (IRRs) with 95% confidence intervals (CI) of ILD development. Using multivariable cox regression analyses, we estimated hazard ratios (HRs) with 95% CIs of ILD in various SARD groups compared with their comparison groups after adjusting for age, sex, Charlson comorbidity index, amiodarone use and methotrexate use. Sensitivity analyses were conducted by using a narrow definition of ILD.

Results: As shown in Table 1, the IRs of ILD were greatest in SSc patients (2,523 per 10⁵ years), followed by patients with DMtis (2,463 per 10⁵ years), PM (1,956 per 10⁵ years), SS (601 per 10⁵ years), RA (279 per 10⁵ years), and SLE (276 per 10⁵ years). Multivariable analyses showed that the risks of ILD were significantly increased in patients with SSc (HR, 66.01; 95% CI, 32.73–133.13), DMtis (128.74, 95% CI, 40.19–412.47), PM (HR, 30.39; 95% CI, 11.24–82.15), pSS (HR, 8.76; 95% CI, 7.03–10.90), RA (HR, 4.22; 95% CI, 3.51–5.08), and SLE (HR, 13.98; 95% CI, 9.25–21.14).

Table 1. Comparison of incidence rates of interstitial lung disease among patients with SARD

SARD	Total	Event (%)	Person-years	Incidence rate (/10 ⁵ years)	IRR (95% CI)
SARD					
Control	253,108	781 (0.3)	1,601,941	49	Reference
SARD	63,277	1,660 (2.6)	380,783	436	8.9 (8.2–9.7)
DMtis					
Control	3,716	10 (0.3)	25,508	39	Reference
DMtis	929	116 (12.5)	4,710	2,463	62.8 (32.9–119.9)
PM					
Control	2,828	9 (0.3)	18,647	48	Reference
PM	707	72 (10.2)	3,681	1,956	40.5 (20.3–81.0)
SSc					
Control	6,224	16 (0.3)	40,789	39	Reference
SSc	1,556	205 (12.2)	8,124	2,523	64.3 (38.7–107.0)
SLE					
Control	52,236	81 (0.2)	366,437	22	Reference
SLE	13,059	230 (1.8)	83,346	276	12.5 (9.7–16.1)
pSS					
Control	60,684	191 (0.3)	326,589	58	Reference
pSS	15,171	471 (3.1)	78,406	601	10.3 (8.7–12.2)
RA					
Control	127,420	474 (0.4)	823,970	58	Reference
RA	31,855	566 (1.8)	202,516	279	4.9 (4.3–5.5)

Conclusion: This nationwide, population-based, matched cohort study demonstrated that the risks of ILD were significantly increased in patients with SARDs.

References:

- [1] Su R, Bennett M, Jacobs S, Hunter T, Bailey C, Krishnan E, et al. An analysis of connective tissue disease-associated interstitial lung disease at a US Tertiary Care Center: better survival in patients with systemic sclerosis. *The Journal of rheumatology*. 2011;38(4):693–701.
- [2] Hu Y, Wang LS, Wei YR, Du SS, Du YK, He X, et al. Clinical Characteristics of Connective Tissue Disease-Associated Interstitial Lung Disease in 1,044 Chinese Patients. *Chest*. 2016;149(1):201–8. Araki T, Putman RK, Hatabu H, Gao W, Dupuis J, Latourelle JC, et al. Development and Progression of Interstitial Lung Abnormalities in the Framingham Heart Study. *Am J Respir Crit Care Med* 2016;194:1514–1522.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.205

SAT0583 DIPEPTIDYL PEPTIDASE-4 AND RISK OF PSORIASIS IN PATIENTS WITH TYPE 2 DIABETES

W. S. Chen¹, Y. S. Chang², C. Y. Tsai¹, C. C. Chang³. ¹Division of Allergy, Immunology & Rheumatology, Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China; ²Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Shuang Ho Hospital, Taipei, Taiwan, Republic of China; ³Division of Rheumatology, Immunology and Allergy, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan, Republic of China

Background: The risk of psoriasis in diabetic patients has rarely been explored. **Objectives:** This study aimed to investigate the association between dipeptidyl peptidase-4 (DPP4) inhibitors and the risk of psoriasis in type 2 diabetes mellitus (T2DM) patients.

Methods: We conducted a population-based propensity score-matched cohort study on the basis of Taiwan's National Health Insurance Research Database that included initiators of combination therapy with DPP4i (DPP4i plus metformin) and sulfonylurea (sulfonylurea plus metformin). Psoriasis (PSO) was identified with ≥ 2 diagnoses. Diabetes complications severity index (DCSI) was calculated. A total of 22721 DPP4 initiator and 227684 sulfonylurea initiator were identified. A 1:10 matched-pair cohort based on propensity score (PS) was created. PS-stratified Cox proportional hazards models compared the risk of PSO in DPP4i versus sulfonylurea initiator within 2 years, controlling for potential confounders.

Results: After propensity score matching, 9962 patients with T2DM starting DPP4i combination therapy and 39848 starting sulfonylurea combination therapy were selected. The incidence rate of PSO was lower in DPP4i group (188/100000 person-years) than in sulfonylurea group (467/100000 person-years). Risks of